###begin article-title 0
Association Analysis of Type 2 Diabetes Loci in Type 1 Diabetes
###end article-title 0
###begin p 1
###xml 41 60 41 60 <email xmlns:xlink="http://www.w3.org/1999/xlink">hakonarson@chop.edu</email>
###xml 92 126 92 126 <email xmlns:xlink="http://www.w3.org/1999/xlink">constantin.polychronakos@mcgill.ca</email>
Corresponding authors: Hakon Hakonarson, hakonarson@chop.edu, and Constantin Polychronakos, constantin.polychronakos@mcgill.ca
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit,and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
###xml 112 117 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 119 125 119 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KCNJ11</italic>
###xml 127 131 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WFS1</italic>
###xml 133 138 133 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HNF1B</italic>
###xml 140 143 140 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IDE</italic>
###xml 144 148 144 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HHEX</italic>
###xml 150 157 150 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC30A8</italic>
###xml 159 165 159 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKAL1</italic>
###xml 167 173 167 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A</italic>
###xml 174 175 174 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 177 184 177 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
###xml 190 193 190 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FTO</italic>
###xml 194 202 194 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPGRIP1L</italic>
OBJECTIVE-To search for a possible association of type 1 diabetes with 10 validated type 2 diabetes loci, i.e., PPARG, KCNJ11, WFS1, HNF1B, IDE/HHEX, SLC30A8, CDKAL1, CDKN2A/B, IGF2BP2, and FTO/RPGRIP1L.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 74 75 74 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 164 165 164 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
RESEARCH DESIGN AND METHODS-Two European population samples were studied: 1) one case-control cohort of 514 type 1 diabetic subjects and 2,027 control subjects and 2) one family cohort of 483 complete type 1 diabetic case-parent trios (total 997 affected). A total of 13 tag single nucleotide polymorphisms (SNPs) from the 10 type 2 diabetes loci were analyzed for type 1 diabetes association.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 247 255 247 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A/B</italic>
###xml 288 289 288 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
RESULTS-No association of type 1 diabetes was found with any of the 10 type 2 diabetes loci, and no age-at-onset effect was detected. By combined analysis using the Wellcome Trust Case-Control Consortium type 1 diabetes data, SNP rs1412829 in the CDKN2A/B locus bordered on significance (P = 0.039) (odds ratio 0.929 [95% CI 0.867-0.995]), which did not reach the statistical significance threshold adjusted for 13 tests (alpha = 0.00385).
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
CONCLUSIONS-This study suggests that the type 2 diabetes loci do not play any obvious role in type 1 diabetes genetic susceptibility. The distinct molecular mechanisms of the two diseases highlighted the importance of differentiation diagnosis and different treatment principles.
###end p 6
###begin p 7
Published ahead of print at  on 21 April 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 293 294 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 419 420 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 710 711 707 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
Type 1 and type 2 diabetes both result from the metabolic consequences of inadequate insulin effect and have similar complications but appear to be due to completely distinct pathogenetic mechanisms. Type 1 diabetes results from autoimmune beta-cell destruction leading to insulin deficiency (1), whereas type 2 diabetes is the end point of a progressive insulin secretory defect on a background of insulin resistance (1). Both diseases are of multifactorial etiology, in which genetic predisposition plays a critical role and behaves as a complex trait. The risk to case-siblings relative to the general population is estimated to be as high as 4- to 6-fold in type 2 diabetes and 15-fold in type 1 diabetes (2).
###end p 9
###begin p 10
###xml 130 131 130 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 399 400 393 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 475 476 469 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
Despite the difference in the basic pathogenetic processes for each type, an overlap in genetic predisposition has been proposed (3) and is quite plausible. For example, not all individuals with evidence of beta-cell autoimmunity will develop clinical type 1 diabetes, a situation in which the factors responsible for impaired beta-cell function and survival in type 2 diabetes may tip the balance (3). The role of inflammation in type 2 diabetes is increasingly recognized (4) and suggests another common link.
###end p 10
###begin p 11
###xml 64 67 64 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 134 135 134 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 171 174 171 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 248 249 248 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 263 264 263 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 306 312 306 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 736 741 736 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 794 800 790 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KCNJ11</italic>
###xml 866 872 862 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 906 910 902 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WFS1</italic>
###xml 937 942 933 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HNF1B</italic>
###xml 1061 1064 1057 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IDE</italic>
###xml 1065 1069 1061 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HHEX</italic>
###xml 1071 1078 1067 1074 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC30A8</italic>
###xml 1080 1086 1076 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKAL1</italic>
###xml 1088 1094 1084 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A</italic>
###xml 1095 1096 1091 1092 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1098 1105 1094 1101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
###xml 1111 1114 1107 1110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FTO</italic>
###xml 1115 1123 1111 1119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPGRIP1L</italic>
###xml 1125 1126 1121 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 1127 1129 1123 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
Of the known type 1 diabetes-associated loci, the insulin gene (INS) has been examined, and no type 2 diabetes association was found (5). A parent-specific association of INS has been (5) but has not been replicated by another study. Recently, we (6) and others (7) examined the major type 2 diabetes gene TCF7L2 for possible type 1 diabetes association and found none. However, there has been no systematic examination of locus overlap between the two diseases; this gap in our understanding of diabetes has become more important with the proliferation of solidly replicated loci as a result of genome-wide association (GWA) studies enabled by recent technical breakthroughs. For type 2 diabetes, 11 loci have been validated involving PPARG (peroxisome proliferator-activated receptor gamma), KCNJ11 (potassium inwardly rectifying channel, subfamily J, member 11), TCF7L2 (transcription factor 7-like 2), WFS1 (Wolfram syndrome 1), and HNF1B (hepatocyte nuclear factor 1 homeobox B) and 6 novel type 2 diabetes-associated loci identified by GWA studies, i.e., IDE/HHEX, SLC30A8, CDKAL1, CDKN2A/B, IGF2BP2, and FTO/RPGRIP1L (8-13). The purpose of this study was to scrutinize data from our recent GWA study of type 1 diabetes in order to search for possible evidence of associated type 2 diabetes susceptibility loci.
###end p 11
###begin title 12
RESEARCH DESIGN AND METHODS
###end title 12
###begin title 13
Subjects and genotyping.
###end title 13
###begin p 14
###xml 37 39 37 39 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 366 371 <span type="species:ncbi:9606">child</span>
###xml 439 447 <span type="species:ncbi:9606">children</span>
###xml 577 585 <span type="species:ncbi:9606">patients</span>
###xml 910 918 <span type="species:ncbi:9606">Children</span>
###xml 964 972 <span type="species:ncbi:9606">Children</span>
As described in our previous report (14), two European-descent samples were studied. The first consisted of 514 type 1 diabetic subjects and 2,027 control subjects (representing the addition of 969 healthy control subjects to the set described by Hakonarson et al. [14] in order to increase statistical power) and 483 complete type 1 diabetes family trios (affected child and both parents). The average age at onset of the type 1 diabetic children was mean +/- SD 7.89 +/- 4.05. The median age was 8 years, with lower and upper quartiles at 4.6 and 11 years, respectively. All patients were diagnosed under the age of 18 years and treated with insulin since diagnosis, and none have stopped treatment for any reason. Ethnic backgrounds were of mixed European descent. All samples were genotyped on the Illumina Infinium II HumanHap550 array (Illumina, San Diego, CA). The Research Ethics Board of the Montreal Children's Hospital, the Research Ethics Board of the Children's Hospital of Philadelphia, and other participating centers approved the study, and written informed consent was obtained from all subjects.
###end p 14
###begin title 15
Type 2 diabetes-associated single nucleotide polymorphisms.
###end title 15
###begin p 16
###xml 12 19 12 19 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 280 285 280 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 402 408 398 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKAL1</italic>
###xml 446 447 442 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 447 448 443 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 466 474 462 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A/B</italic>
###xml 512 513 508 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 513 514 509 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 532 540 528 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IDE/HHEX</italic>
###xml 578 579 574 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 579 580 575 576 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 625 631 621 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KCNJ11</italic>
###xml 714 715 710 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 715 716 711 712 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 736 737 732 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 794 795 790 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 796 798 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 917 921 911 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WFS1</italic>
As shown in Table 1, 13 type 2 diabetes-associated single nucleotide polymorphisms (SNPs) from the 10 type 2 diabetes loci were selected for the type 1 diabetes analysis. They represent either the SNP originally reported as type 2 diabetes associated or a near-perfect proxy. The PPARG SNP rs1801282 is located at the first coding exon of PPAR-gamma2 and causes the amino acid change Pro12Ala. The two CDKAL1 SNPs rs4712523 and rs7756992 have an r2 = 0.747. The two CDKN2A/B SNPs rs1412829 and rs2383208 have an r2 = 0.002. The two IDE/HHEX SNPs rs1111875 and rs7923837 have an r2 = 0.744. The type 2 diabetes association of KCNJ11 was found from a non-synonymous SNP Glu23Lys (rs5219) at first. The rs5219 has an r2 = 0.9 with rs5215 (8) and therefore is well tagged by rs5215 in GWA studies (8,10). All of the 13 SNPs have a genotyping success rate >/=98.7% and no Mendelian error in the 483 family trios. Only the WFS1 SNP rs10012946 showed borderline nominal significance of divergence from Hardy-Weinberg equilibrium in the control group, which did not reach the significance threshold adjusted for 13 tests (alpha = 0.00385).
###end p 16
###begin title 17
Statistical methods.
###end title 17
###begin p 18
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 584 585 584 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">z</italic>
###xml 748 750 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 1048 1049 1048 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Z</italic>
For the case-control cohort, the potential population stratification was corrected using the Eigenstrat algorithm (19) implemented in the Eigensoft version 2.0 software (). By the principal components analysis of population structure (19), 42 case and 130 control subjects were identified and removed as outliers. Therefore, 472 type 1 diabetic case and 1,897 control subjects were analyzed for genetic association. For the family cohort, the transmission disequilibrium test was performed using the Haploview software (). For a joint analysis of the two cohorts, we combined the two z scores weighted by the sample sizes. According to the statistical power calculation for a case-control study with unequal sample sizes proposed by Fleiss et al. (20), the case-control cohort of 472 type 1 diabetic case and 1,897 control subjects has the statistical power equivalent to 756 case vs. 756 control subjects. The family cohort of 483 complete type 1 diabetic trios has the statistical power equivalent to 483 case vs. 483 control subjects. The joint Z score was calculated as:
###end p 18
###begin p 19
###xml 6 7 6 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Z</italic>
###xml 7 8 7 8 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 43 44 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Z</italic>
###xml 44 45 44 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 76 77 76 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Z</italic>
###xml 138 139 136 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 219 220 217 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Z</italic>
###xml 301 302 299 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Z</italic>
where Z1 is of the case-control cohort and Z2 is of the family cohort. Each Z score is equivalent to the square root of the respective chi2 value. A protective or undertransmitted minor allele corresponds to a negative Z score, whereas a risk or overtransmitted minor allele corresponds to a positive Z score.
###end p 19
###begin title 20
RESULTS AND DISCUSSION
###end title 20
###begin p 21
###xml 26 33 26 33 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 291 297 291 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 720 730 718 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Affymetrix</italic>
###xml 742 743 740 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 784 791 782 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t3">Table 3</xref>
###xml 945 953 943 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A/B</italic>
###xml 1029 1030 1023 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1106 1107 1100 1101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1140 1146 1134 1140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A</italic>
###xml 1151 1157 1145 1151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B</italic>
###xml 1235 1240 1229 1234 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 1248 1253 1242 1247 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4b</sup>
###xml 1345 1347 1336 1338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
As shown by our analysis (Table 2), none of the 13 SNPs from the 10 type 2 diabetes loci show statistically significant association. These 13 SNPs have a minor allele frequency range from 0.116 to 0.397. The statistical power of this study to detect an association from each SNP is shown in Fig. 1. Our study had sufficient power to detect an association with OR >/=1.20 for each SNP with different allele frequency. To further increase statistical power, we performed a combined analysis using the publicly available Wellcome Trust Case-Control Consortium (WTCCC) data (supplementary Table 1 [available in an online appendix at ]). The WTCCC tested 2,000 type 1 diabetic case and 3,000 control subjects for 500 k SNPs (Affymetrix GeneChip) (8). As shown by the association analysis (Table 3), 12 of the 13 SNPs did not show statistical significance in either the WTCCC data alone or the combined analysis with our dataset. SNP rs1412829 in the CDKN2A/B locus met the significance threshold of alpha = 0.00385 in the WTCCC data (P = 0.002) (OR 0.879 [95% CI 0.810-0.954]) but not in the combined analysis (P = 0.039) (0.929 [0.867-0.995]). CDKN2A and CDKN2B encode two specific inhibitors of cyclin-dependent kinase 4 (CDK4), i.e., p16INK4a and p15INK4b, respectively. CDK5 and CDK4 play important roles in beta-cell function and proliferation (10), and, as such, the locus is a reasonable functional candidate. Study of much larger cohorts will be needed to evaluate the possibility of a very weak effect in type 1 diabetes.
###end p 21
###begin p 22
###xml 592 599 589 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
Our study suggests that the type 2 diabetes loci do not play any obvious role in type 1 diabetes genetic susceptibility. These known type 2 diabetes genes are mainly involved in two mechanisms, i.e., pancreatic beta-cell function and peripheral insulin sensitivity. To explore whether these genes may promote the early onset of type 1 diabetes by impairing insulin secretion or insulin sensitivity, we also investigated the age-at-onset difference of different genotypes for each type 2 diabetes SNP marker. As shown by the one-way ANOVA test of age at onset of three genotypes for each SNP (Table 2), no SNP has an obvious effect on the type 1 diabetes age at onset. Unlike type 2 diabetes, type 1 diabetes typically has an acute onset that can be reliably defined.
###end p 22
###begin p 23
###xml 760 768 760 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A/B</italic>
###xml 1635 1637 1631 1633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 623 631 <span type="species:ncbi:9606">patients</span>
Both type 1 and type 2 diabetes are complex diseases. With the rapid technological development of functional genomics, distinct molecular mechanisms of the two diseases are being recognized, establishing the basis of different approaches for developing novel preventive or therapeutic strategies for type 1 and type 2 diabetes. In addition, this study highlights the importance of differentiation diagnosis of adult-onset type 1 diabetes from type 2 diabetes. Because type 1 diabetes does not share common genetic susceptibility with type 2 diabetes, it is important to manage different treatment for adult type 1 diabetic patients. Some issues remain for further studies on genetic mechanisms of type 1 and type 2 diabetes. The type 1 diabetes association of CDKN2A/B needs to be confirmed by an independent study with a large sample size. Assuming a multiplicative effects model, an OR of 0.929, and a minor allele frequency of 0.452, a study with 5,790 case and 5,790 control subjects has 80% statistical power to replicate the association at alpha = 0.05. Both our study and the WTCCC study focused on pediatric-onset type 1 diabetes, and the possibility remains that type 2 diabetes loci may have some effect in adult-onset cases. Finally, the involvement of type 1 diabetes loci in type 2 diabetes genetics needs further investigation, the testing of which will require accurate phenotyping within the clinical spectrum of type 2 diabetes. For example, it will be interesting to study all type 1 diabetes loci in the subset of insulin-resistant, non-insulin-treated, adult-onset cases that are positive for islet autoantibodies (21).
###end p 23
###begin title 24
Supplementary Material
###end title 24
###begin title 25
Online-Only Appendix
###end title 25
###begin p 26
###xml 28 36 <span type="species:ncbi:9606">Children</span>
This work was funded by the Children's Hospital of Philadelphia, the Juvenile Diabetes Research Foundation International, and Genome Canada. H.Q.Q. is supported by a fellowship from the Canadian Institutes of Health Research.
###end p 26
###begin p 27
###xml 17 25 <span type="species:ncbi:9606">patients</span>
We thank all the patients, their parents, and the healthy control subjects for their participation in the study.
###end p 27
###begin title 28
REFERENCES
###end title 28
###begin p 29
###xml 141 146 137 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 185 193 181 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A/B</italic>
###xml 232 239 228 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC30A8</italic>
###xml 263 269 259 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKAL1</italic>
The statistical power of this study to detect genetic associations with different minor allele frequencies (MAFs) at alpha = 0.05 level. The PPARG SNP rs2197423 has an MAF = 0.116; the CDKN2A/B SNP rs2383208 has an MAF = 0.176; the SLC30A8 SNP rs13266634 and the CDKAL1 SNP rs7756992 have similar MAFs, average 0.294; the other nine SNPs, rs4402960, rs4712523, rs5215, rs10012946, rs7923837, rs1412829, rs1111875, rs7501939, and rs8050136, have similar MAFs, average 0.364. x-axis, OR value; y-axis, statistical power.
###end p 29
###begin p 30
Type 2 diabetes-associated SNPs for the type 1 diabetes analysis
###end p 30
###begin p 31
HW, Hardy-Weinberg equilibrium test of the control group in the case-control cohort.
###end p 31
###begin p 32
Type 1 diabetes association analysis
###end p 32
###begin p 33
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Z</italic>
Z score of the case-control cohort.
###end p 33
###begin p 34
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Z</italic>
Z score of the family cohort.
###end p 34
###begin p 35
###xml 9 10 9 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Z</italic>
###xml 21 22 21 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Combined Z value and P value.
###end p 35
###begin p 36
One-way ANOVA test of age-at-onset difference of three genotypes. MA, minor allele; MAF, minor allele frequency.
###end p 36
###begin p 37
Combined analysis of the WTCCC data and our data
###end p 37
###begin p 38
###xml 55 56 55 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Z</italic>
The WTCCC data were combined with our data by weighted Z scores. The WTCCC 2,000 case and 3,000 control subjects have the statistical power equivalent to 2,400 case vs. 2,400 control subjects.
###end p 38

